HEALTH PROFESSIONAL · SOURCE READING

Binimetinib

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Signal transduction inhibitors / MEK inhibitors

Binimetinib is an orally available, small-molecule, selective MEK1 and MEK2 inhibitor. The FDA approved binimetinib in 2018 for use in combination with the BRAF inhibitor encorafenib.

Preserved source evidence · Not medical advice